Truist Securities Maintains Buy on Genmab, Maintains $50 Price Target
Portfolio Pulse from Benzinga Newsdesk
Truist Securities analyst Asthika Goonewardene maintains a Buy rating on Genmab (NASDAQ:GMAB) with a maintained price target of $50.
March 26, 2024 | 1:29 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Truist Securities maintains a Buy rating on Genmab with a $50 price target.
The reaffirmation of a Buy rating and a specific price target by a reputable analyst like Asthika Goonewardene from Truist Securities typically signals a positive outlook on the stock, suggesting potential upside. This could lead to increased investor confidence and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100